

Special Issue

Genomic Insights in Dermatology: The Future of Personalised Medicine for Skin Disease

Message from the Guest Editor

Since the rediscovery of Mendel's work in the early 20th century, scientists have worked hard to understand the contribution of genetics to human diseases. It is only relatively recently that the technology has developed to the stage where truly personalised medicine is becoming a reality. Diseases of the skin are incredibly common, and while monogenic disorders are known (such as epidermolysis bullosa) in the majority of cases any underlying genetic contribution will be complex. Skin disorders can be life-long, with physical and psychological consequences. This Special issue seeks to address the state of the art in our ability to predict, diagnose, and manage this group of disorders.

Guest Editor

Dr. Kenneth Langlands

Institute of Continuing Education, University of Cambridge, Madingley,
Cambridge CB23 8AQ, UK

Deadline for manuscript submissions

closed (25 May 2025)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/222996

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))